Peptides for immune support: what the evidence shows
Which immune peptides are studied, what the human trials found, what is still unknown, and why an infection needs a diagnosis before anything else. No promises, only sources.
Products in this guide
The short answer for each situation.
| If your situation is | The approach | What is in it | Price |
|---|---|---|---|
| Frequent infections with no diagnosis yet | A medical workup first, not a peptide | No peptide replaces a diagnosis | Your clinician decides |
| Immune support, with a clinician who knows your history | One immune peptide, reviewed before it is prescribed | Thymosin alpha-1, thymalin or LL-37 | Prescribed after a clinician review |
| Inflammation in more than one area | A blend, reviewed before it is prescribed | Thymosin alpha-1, BPC-157, KPV and LL-37 | Prescribed after a clinician review |
| Sepsis or a serious infection | Hospital care first. A large sepsis trial found no clear effect on deaths | No peptide replaces hospital treatment | Your clinician decides |
Each product has its composition and concentration on its card. Products without a public price are prescribed after a clinician review.
How the immune response works, and where the evidence stops.
An immune response moves through steps that overlap: the body detects a threat, sends signals between cells, and then turns the response down. The peptides in this guide were studied in those steps, mostly in cells and animals. A large trial in sepsis did not find a clear effect on death [1].
Detection
Cells recognize microbes or damage. LL-37 is an antimicrobial peptide. A review of its role in rosacea calls for human studies [7].
Signalling
Immune cells send messages to coordinate the response. KPV is one of the related tripeptides of alpha-MSH, studied for anti-inflammatory effects in cells and animals [5].
T lymphocytes
Thymalin is a thymus-derived preparation. Its effect on the maturation of T cells has been shown in laboratory work on human stem cells [6].
Resolution
The response is turned down once the threat is cleared. Thymosin alpha-1 is an immunomodulator, and trials in sepsis and chronic hepatitis B have given unclear results [1][3].
The four steps are a simplification to help you read this guide. They are not a protocol.
The products, one by one.
Each card shows what is in the vial and its concentration, as the pharmacy prepares it. Your clinician decides whether a product fits your case and at what dose. We publish no dose figures here: for most of these peptides there is no established dose in people.
Single peptides
Thymosin Alpha-1
- Composition and concentration
- 1 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
From $209/mo
View productLL-37
- Composition and concentration
- 1 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
Prescribed after a clinician review
Start intakeThymalin
- Composition and concentration
- 1 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
Prescribed after a clinician review
Start intake
Blends
Thymosin Alpha-1 / BPC-157 / KPV / LL-37
- Composition and concentration
- 1 mg / 1 mg / 0.4 mg / 0.2 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
Prescribed after a clinician review
Start intake
What the evidence shows and what it does not.
Most of what has been published comes from cells, animals and reviews. The human trials are few, and the largest one did not confirm a benefit on its main outcome.
What exists
- A phase 3 trial in 1,106 adults with sepsis, which found no clear evidence that thymosin alpha-1 lowers deaths at 28 days [1].
- A meta-analysis of sepsis trials that found possible differences between subgroups, and said the sample is still too small [2].
- A Cochrane review of thymosin alpha-1 in chronic hepatitis B, whose authors say they are not sure it works [3].
- A scoping review of thymosin alpha-1 in cancer care, which calls for controlled studies with standard dosing [4].
- Laboratory and animal studies of KPV and related tripeptides, reviewed for anti-inflammatory effects [5].
What is missing
- Trials in people that show these products prevent infections or make them shorter.
- Large human trials of the blends. We did not find any.
- An established dose in people for most of these peptides.
- Long-term safety data in people for most of these products.
- Supplier pages and online forums. They are not studies, and we do not count them as evidence.
Numbers in brackets point to the reference list at the end of the guide.
Where these stand with the FDA.
Compounded medications are not reviewed by the FDA for safety, efficacy or quality before they are sold. A pharmacy licensed in the United States prepares them with a prescription from a physician. This page does not describe any FDA approval for these peptides.
Who should not use them, and when another option fits better.
These are the cases where a clinician should wait or choose another route. The list is not complete: your clinician reviews your history before any prescription.
| Situation | Why |
|---|---|
| Pregnancy, breastfeeding or trying to conceive | There are not enough data in pregnant people. Your clinician reviews this first. |
| Sepsis, or a fever with signs of a serious infection | This needs assessment in hospital now. A peptide is not a substitute. |
| Active cancer or cancer treatment | The cancer team and your clinician coordinate. The cancer data are mixed and call for controlled studies [4]. |
| An autoimmune disease or a transplant | Changing the immune response matters in these conditions. Your clinician decides before anything else. |
| Kidney or liver disease | These organs process and clear many substances. Your clinician checks your case. |
What to expect, and when.
There are no validated timelines in people for these peptides. In the sepsis trial, the drug was given in hospital for up to seven days [1]. Outside a study, agree with your clinician what to watch and when to review it.
- What to measure: the infections or symptoms you care about, recorded at the start.
- When to review: at the follow-up visits your clinician schedules.
- What not to expect: a peptide that replaces a diagnosis, a vaccine or an antibiotic when one is needed.
Tests and monitoring your clinician decides.
Your clinician decides which tests to order before you start and during treatment, based on your history. Infections that keep coming back are checked first.
- Before: your full history, your infection history, and the examination your clinician considers necessary.
- During: review at the visits, with the tests your clinician orders.
References
Only studies and reviews indexed in PubMed, with the title and year as they appear there.
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 2025
- Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol, 2025
- Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev, 2026
- Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. Pharmaceuticals (Basel), 2026
- Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev, 2008
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med, 2020
- LL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies. Clin Cosmet Investig Dermatol, 2026
Common questions
Which immune peptide is best?
None has shown a clear benefit in a large trial in people for infections. Your clinician chooses according to your history and the reason you are asking.
Do they prevent infections?
We did not find human trials that show it. The data come mostly from cells, animals and a few clinical studies in other conditions.
Does thymosin alpha-1 help in sepsis?
A large trial did not show a clear reduction in deaths at 28 days [1]. A meta-analysis found possible differences between subgroups, and said more trials are needed [2].
Are they legal?
They are compounded medications. They are not FDA-approved for safety, efficacy or quality. A pharmacy licensed in the United States prepares them with a prescription.
How much do they cost?
Products with a public price show it on their page. The others are prescribed after a clinician review, so start with the intake to learn about your case.
Can the blend be used instead of single peptides?
The blend is sold as one product, but we found no large human trials of that combination. Your clinician decides whether it makes sense for you.
Start with your case and a clinician.
Complete the intake. A physician in our practice reviews your history before anything is prescribed.
